
Stallergenes SA Profile last edited on: 4/7/2022
Desensitization therapies for the prevention and treatment of allergy-related respiratory diseases Year Founded
1962Last Involved Year
2013Key People / Management
Location Information
6 Rue Alexis De Tocqueville Cedex
Antony, FR 92183
Antony, FR 92183
(331) 555-92000 |
www.stallergenes.fr |
Public Profile
Stallergenes SA is a French biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis, rhinitis and allergic asthma. It has developed a range of in vivo and in vitro tests for use in the medical profession. The Company's range of products includes more than 150 references. The Company also has research and development teams divided between clinical development, laboratory research and development of candidate products, and regulatory affairs. Stallergenes SA is present in almost 40 countries via ten subsidiaries in Europe in Germany, Italy, Spain, Belgium, Switzerland, the Netherlands, the Czech Republic, Slovakia, Austria and Great Britain, and has entered into numerous partnerships and distribution agreements. As of December 31, 2011, Stallergenes SA was 73.4%-owned by Ares Life Sciences.
Extent of SBIR involvement
Synopsis: Techseeker Business Condition
Headquartered
FranceEmployment
1,100Revenue
$308.1MPublic/Private
Publicly TradedStock Info
EuroNext P : GENP.PAReceived SBIR $$
NoTechseeker firm in the news
There are no news available.